Browse Category

NASDAQ:HBAN News 23 October 2025 - 7 February 2026

Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

Cadence Bank shares have been delisted following Huntington Bancshares’ takeover, with each Cadence share converted into 2.475 Huntington shares. Huntington closed Friday at $19.27 and named Senthil Kumar as chief risk officer ahead of new regulatory requirements. The merger leaves Cadence as a brand under Huntington, with customer account conversions planned for mid-2026. Huntington executives will address investors at a UBS conference on Tuesday.
Cadence Bank stock price: CADE stops trading after Huntington deal — what shareholders get now

Cadence Bank stock price: CADE stops trading after Huntington deal — what shareholders get now

Huntington Bancshares completed its all-stock merger with Cadence Bank on Feb. 1, ending Cadence’s run as an independent public company. Cadence shareholders received 2.475 Huntington shares per Cadence share, with cash for fractions. Huntington now holds about $279 billion in assets and nearly 1,400 branches. HBAN shares traded at $18.95 midday, valuing former Cadence shares at roughly $46.90.
Cadence Bank stock: what CADE shareholders get now that Huntington deal is done

Cadence Bank stock: what CADE shareholders get now that Huntington deal is done

Huntington Bancshares shares rose 2.2% premarket after completing its $7.4 billion all-stock acquisition of Cadence Bank. Each Cadence share was exchanged for 2.475 Huntington shares, valuing Cadence at about $44.25 per share. Huntington issued 462 million shares and absorbed Cadence’s operations and branches. The combined bank will hold $279 billion in assets.
Why Huntington Bancshares Incorporated stock is up after the Cadence merger close

Why Huntington Bancshares Incorporated stock is up after the Cadence merger close

Huntington Bancshares shares rose 1.9% to $17.82 after the bank completed its $7.4 billion all-stock merger with Cadence Bank. The combined bank now holds $279 billion in assets and claims the top deposit market share in Mississippi. Cadence shareholders received 2.475 Huntington shares per Cadence share. Investors are watching for integration costs and the timing of customer account transitions, set for mid-2026.
Cadence Bank stock price: CADE turns into Huntington Bancshares shares after deal closes

Cadence Bank stock price: CADE turns into Huntington Bancshares shares after deal closes

Cadence Bank shares ceased trading after Huntington completed its $7.4 billion all-stock acquisition on Feb. 1, with each Cadence share converted into 2.475 Huntington shares. Huntington stock rose 0.7% premarket to $17.48, implying about $43.26 per Cadence share. Account conversions are set for mid-2026. Three former Cadence directors, including CEO Dan Rollins, join Huntington’s board.
Huntington Bancshares stock wobbles in premarket as traders eye Cadence merger timing and index flows

Huntington Bancshares stock wobbles in premarket as traders eye Cadence merger timing and index flows

Huntington Bancshares slipped 0.3% to $17.42 in premarket trading Monday after gaining 1.1% Friday. The Cadence Bank merger is expected to close around Feb. 1, with FTSE Russell set to adjust index weights Feb. 2 if the deal completes. Investors remain focused on Huntington’s 2026 net interest income outlook and await final confirmation of the merger’s closing.
Cadence Bank stock slides on merger countdown — what CADE holders are watching for Monday

Cadence Bank stock slides on merger countdown — what CADE holders are watching for Monday

Cadence Bank shares fell 1.7% to $42.11 Friday, with volume surging ahead of its pending merger with Huntington Bancshares. Huntington expects the deal to close around Feb. 1, having secured all regulatory approvals. The merger spread narrowed to about 2.7% below Huntington’s implied value. Traders await confirmation of the merger’s completion and details on when CADE will halt trading.
Cadence Bank stock slips as Huntington deal countdown nears Feb. 1 close

Cadence Bank stock slips as Huntington deal countdown nears Feb. 1 close

Cadence Bank shares fell 1.7% to $42.11 Friday, widening their discount to the implied Huntington Bancshares takeover price ahead of the expected Feb. 1 merger close. Huntington ended up 1.1% at $17.48, raising the deal’s implied value to $43.26 per Cadence share. All regulatory approvals are in place, with final closing conditions pending. After-hours, Cadence rose to $42.41.
HBAN stock: Huntington Bancshares heads into the week with a $1.75bn debt raise and Cadence merger clock ticking

HBAN stock: Huntington Bancshares heads into the week with a $1.75bn debt raise and Cadence merger clock ticking

Huntington Bancshares shares fell 1.6% Friday to $17.35 after announcing $1.75 billion in new notes, set to settle Jan. 28. The $7.4 billion Cadence Bank merger is expected to close near Feb. 1, with all regulatory approvals secured. Huntington reported Q4 net income of $519 million and kept its quarterly dividend at $0.155 per share. Investors are watching funding costs and integration risks as the deal nears completion.
Huntington Bancshares stock tees up a big week after Cadence merger green light and new debt sale

Huntington Bancshares stock tees up a big week after Cadence merger green light and new debt sale

Huntington Bancshares secured all regulatory approvals for its merger with Cadence Bank and launched a $1.75 billion debt offering. Shares fell 1.6% Friday to $17.35. Fourth-quarter net income reached $519 million, with deposits up $8.3 billion from the prior quarter. The bank expects net interest income to rise 10%–13% in 2026, boosted by the Cadence deal.
HBAN stock slips as Huntington tees up new debt sale ahead of Cadence deal — what to watch next week

HBAN stock slips as Huntington tees up new debt sale ahead of Cadence deal — what to watch next week

Huntington Bancshares shares fell about 1% to $17.47 Friday afternoon amid a broader selloff in regional banks. The company reported Q4 net income of $519 million and plans to close its Cadence Bank acquisition in early February. Huntington is preparing a note offering, including floating-rate bonds, and maintained its quarterly dividend at 15.5 cents per share. Investors are watching integration costs and net interest income guidance.
HBAN stock price tumbles after Huntington earnings — what investors are watching next

HBAN stock price tumbles after Huntington earnings — what investors are watching next

Huntington Bancshares shares fell 5.9% to $17.64 in after-hours trading Thursday after fourth-quarter results showed net income dropped to $519 million, or 30 cents per share. Noninterest expense rose to $1.42 billion, and provision for credit losses increased to $123 million. The board kept the dividend steady at $0.155 per share. Management forecasts 2026 net interest income to rise 10%–13% before the Cadence deal.
Star Tribune’s Bold “Good News” Experiment – Can Positive Stories Save Local News?

Star Tribune’s Bold “Good News” Experiment – Can Positive Stories Save Local News?

Forecast & Analysis: The next few months will reveal how readers respond to MN Rising. Early indicators (like social media buzz and pageview stats) will be crucial. Advertisers will be watching closely for engagement metrics – if these stories attract eyeballs and positive sentiment, sponsors will be encouraged to renew and new ones will sign up. The Star Tribune might also integrate MN Rising content into its main news products (print, newsletters, etc.) to give it wider exposure. We may see events or forums spin out of it as well (e.g. an awards event for companies doing good, sponsored by
23 October 2025

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop